[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363993-105":59,"doc-detail-363993-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrated-computational-and-preclinical-evaluation-of-drug-repurposing-candidates-for-kras-mutant-non-small-cell-lung-cancer-abstract","Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer - abstract","","KRAS mutations, especially KRAS G12C, create therapeutic challenges in non-small cell lung cancer (NSCLC) because inhibitor effects are limited and resistance emerges rapidly. A structure-based drug repurposing pipeline screened FDA-approved compounds against key MAPK pathway regulators and modeled binding to the KRAS G12C switch-II pocket. Virtual screening, molecular docking, and molecular dynamics assessed binding affinity and stability, followed by in vitro functional tests and ex ovo CAM and in vivo chemically induced lung carcinoma models. Nilotinib showed marked reductions in viability, colony formation, angiogenesis, migration, and induced apoptosis, also lowering tumor burden and reshaping immune and inflammatory profiles, supporting it as a promising candidate.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-computational-and-preclinical-evaluation-of-drug-repurposing-candidates-for-kras-mutant-non-small-cell-lung-cancer-abstract/363993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-computational-and-preclinical-evaluation-of-drug-repurposing-candidates-for-kras-mutant-non-small-cell-lung-cancer-abstract/363993.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KRAS G12C considered a difficult target in NSCLC?","Question",{"text":112,"@type":113},"KRAS mutations, particularly KRAS G12C, show limited inhibitor efficacy and often lead to rapid resistance, reducing durable clinical benefit.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What computational methods were used to evaluate drug repurposing candidates?",{"text":117,"@type":113},"The study used virtual screening, molecular docking, and molecular dynamics simulations to assess binding affinity, stability, and potential protein-ligand interactions with the KRAS G12C switch-II pocket.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports nilotinib as a promising candidate?",{"text":121,"@type":113},"Functional assays showed nilotinib reduced NSCLC cell viability, colony formation, angiogenesis, inhibited migration, and induced apoptosis, and in vivo it lowered tumor burden while modulating immune and inflammatory profiles.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363993,1790997012,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIntegrated computational and preclinical evaluation of drug repurposing candidates for KRASmutant non-small cell lung cancer  \nAnisha Jain1, Chandan Dharmashekar2, Bhargav Shreevatsa K S2, Kavitha Raj3,  \nAmogha Shivakumar4, Shiva Prasad Kollur6, Chandan Shivamallu5, Ashwini Prasad2 &  \nM. N. Nagendra Prasad1  \nKRAS mutations, particularly KRAS G12C, pose significant therapeutic challenges in non-small cell lung cancer (NSCLC) due to limited inhibitor efficacy and rapid resistance. Drug repurposing offers a time and cost-effective strategy to identify alternative therapeutic options targeting KRAS-driven signalling. A structure-based drug repurposing approach was employed to screen FDA-approved compounds targeting key regulators to the MAPK signalling pathway and computationally modelled for potential engagement with the KRAS G12C switch-II pocket. Computational analyses including virtual screening, molecular docking, and molecular dynamics simulations were used to evaluate binding affinity, stability and potential protein-ligand interactions. Lead candidates were subsequently validated using in vitro functional assays, ex ovo chorioallantoic membrane (CAM) and in vivo chemical induced lung carcinoma model. Computational analyses identified nilotinib and risperidone as high affinity candidates across MAPK pathway targets. Functional assays confirmed that nilotinib markedly reduced NSCLC cell viability, colony formation and angiogenesis, while inhibiting cell migration and inducing apoptosis. In vivo, nilotinib significantly lowered tumor burden and modulated immune and inflammatory profiles in a chemically induced murine lung carcinoma. These findings support nilotinib as a promising therapeutic candidate for KRAS-mutant NSCLC. Further studies involving targetengagement assays, pathway-validation experiments and genetically defined KRAS-G12C driven models are warranted to establish its precise mechanism of action.  \nKeywords Non-small cell lung cancer, KRAS G12C, Nilotinib, MAPK pathway, Drug repurposing, Drug discovery  \nLung cancer remains the leading cause of cancer-related mortality worldwide, accounting for 18.7% of all cancer deaths in 20221. It is the most frequently diagnosed cancer in men (15.2%) and the second in women (9.4%) . In India, incidence and mortality rates were 5.32 and 5.79 per 100,000 population, respectively in 20221,2. Despite therapeutic advances, the overall 5-year survival rate remains below 20%, underscoring the need for novel treatment strategies. Non-small cell lung cancer (NSCLC) constitutes 80–85% of lung cancers, with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma as major subtypes. Over 70% of patients are diagnosed at an advanced stage3,4. Smoking is the principal risk factor, although air pollution, radon, asbestos, diesel exhaust, and genetic predisposition also contribute to carcinogenesis5.  \nThe introduction of targeted therapies and immunotherapies has improved outcomes; however, resistance remains inevitable6. The Mitogen-Activated Protein Kinase (MAPK) signalling pathway comprising receptor tyrosine kinases (RTKs), RAS, RAF, MEK and ERK, is a central driver of proliferation, metastasis, and immune evasion (Supplementary Fig. 1)7. KRAS mutations occur in ~ 30% ofadenocarcinomas, with KRAS G12C being  \n1Department of Biotechnology, JSS Science and Technology University, Mysuru, Karnataka 570006, India.  \n2Department of Microbiology, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India. 3Bioscience CLIx LLP, Mysuru, Karnataka 570023, India. 4Department of Anaesthesiology, KVC Super Speciality Hospital, Mysuru, Karnataka 570004, India. 5Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education & Research, Mysuru, Karnataka 570015, India. 6School of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysuru, Karnataka 570026, India. em","cbCaiiiEpBQQAG9I","https://ap.wps.com/l/cbCaiiiEpBQQAG9I","pdf",4748290,"English","# Background and rationale\n## KRAS mutations and NSCLC burden\n## MAPK signaling and resistance to targeted therapy\n# Repurposing strategy and computational pipeline\n## Structure-based screening and KRAS switch-II modeling\n## Virtual screening, docking, and molecular dynamics\n# Experimental validation\n## In vitro functional assays\n## Ex ovo CAM and in vivo chemical-induced models\n# Findings and implications\n## Lead identification and effects of nilotinib\n## Need for further mechanistic studies","[{\"question\":\"Why is KRAS G12C considered a difficult target in NSCLC?\",\"answer\":\"KRAS mutations, particularly KRAS G12C, show limited inhibitor efficacy and often lead to rapid resistance, reducing durable clinical benefit.\"},{\"question\":\"What computational methods were used to evaluate drug repurposing candidates?\",\"answer\":\"The study used virtual screening, molecular docking, and molecular dynamics simulations to assess binding affinity, stability, and potential protein-ligand interactions with the KRAS G12C switch-II pocket.\"},{\"question\":\"What evidence supports nilotinib as a promising candidate?\",\"answer\":\"Functional assays showed nilotinib reduced NSCLC cell viability, colony formation, angiogenesis, inhibited migration, and induced apoptosis, and in vivo it lowered tumor burden while modulating immune and inflammatory profiles.\"}]","Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer - abstract | PDF",1790154842,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5ed8d23025a36e2a7c8dc6d68647529.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7462a81d43bf2140afb85ff6bf644526.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58f018674393c19cdc4eea9e9995ee64.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6414ce85d21a19294e0a9479fecbd01d.webp",980,1287]